

SUPPLEMENTARY DATA

Details of studies excluded at the full text articles review stage

One article was a systematic review [1]. Four studies were excluded because the sample population only consists of individuals with diabetes [2-4] or excluded those with depression [5]. Five randomised trials from database search and one from hand search did not have an appropriate comparison group [6-11]. Depressive symptoms were not evaluated in one study [12]. Diabetes status was ascertained by oral glucose tolerance test in eight studies [13-20] and impaired fasting glucose test in two [21, 22]).


Supplementary Table 1. Search terms.

1. Depression/
2. Depressive Disorder/
3. Depressive Disorder, Major/
4. Dysthymic Disorder/
5. dysthym*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
6. depress*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
7. 1 or 2 or 3 or 4 or 5 or 6
8. random* controlled trial.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
9. cross-sectional.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
10. case-control.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
11. cohort.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
12. Randomized Controlled Trial/
13. Cross-Sectional Studies/
14. Case-Control Studies/
15. Cohort Studies/
16. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17. Humans/
18. Insulin Resistance/
19. Metabolic Syndrome X/
20. metabolic syndrome.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
21. Insulin/bl, me [Blood, Metabolism]
22. Blood Glucose/
23. Glucose Tolerance Test/
24. insulin sensitiv*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
25. insulin insensitiv*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
26. insulin resistan*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
27. Glucose Intolerance/

SUPPLEMENTARY DATA

28. glucose intoleran*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
29. glucose toleran*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
30. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31. 7 and 16 and 17 and 30

Supplementary Figure 1. Begg's funnel plot with 95% confidence limits of all the studies included in the meta-analysis



Reference

1. Goldbacher, E.M. and K.A. Matthews, *Are psychological characteristics related to risk of the metabolic syndrome? A review of the literature.* Ann Behav Med, 2007. **34**(3): p. 240-52.
2. Hung, Y.J., et al., *Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes.* Diabet Med, 2005. **22**(8): p. 1024-30.
3. Kinder, L.S., et al., *Depressive symptomatology and coronary heart disease in Type 1 diabetes mellitus: a study of possible mechanisms.* Health Psychol, 2002. **21**(6): p. 542-52.
4. Pibernik-Okanovic, M., et al., *Does treatment of subsyndromal depression improve depression and diabetes related outcomes: protocol for a randomised controlled comparison of psycho-education, physical exercise and treatment as usual.* Trials, 2011. **12**: p. 17.
5. Llaneza, P., et al., *Insulin resistance and health-related quality of life in postmenopausal women.* Fertil Steril, 2009. **91**(4 Suppl): p. 1370-3.
6. Chen, Y.C., et al., *Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males.* Mediators Inflamm, 2010. **2010**: p. 573594.

SUPPLEMENTARY DATA

7. Rasgon, N.L., et al., *Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study*. ScientificWorldJournal, 2010. **10**: p. 321-8.
8. Weber-Hamann, B., et al., *Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine*. J Clin Psychopharmacol, 2008. **28**(5): p. 581-4.
9. Weber-Hamann, B., et al., *Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine*. J Clin Psychiatry, 2006. **67**(12): p. 1856-61.
10. Chen, Y.C., et al., *Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males*. J Affect Disord, 2007. **103**(1-3): p. 257-61.
11. Kopf, D., et al., *Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment*. J Clin Psychopharmacol, 2004. **24**(5): p. 527-31.
12. Wei, Y., Y.Z. Hong, and X. Ye, *Effect of Tang No.1 granule (1) in treating patients with impaired glucose tolerance*. Chin J Integr Med, 2008. **14**(4): p. 298-302.
13. Brown, E.S., F.P. Varghese, and B.S. McEwen, *Association of depression with medical illness: does cortisol play a role?* Biol Psychiatry, 2004. **55**(1): p. 1-9.
14. Kivimaki, M., et al., *Hyperglycemia, type 2 diabetes, and depressive symptoms: the British Whitehall II study*. Diabetes Care, 2009. **32**(10): p. 1867-9.
15. Adriaanse, M.C., et al., *Symptoms of depression in people with impaired glucose metabolism or Type 2 diabetes mellitus: The Hoorn Study*. Diabet Med, 2008. **25**(7): p. 843-9.
16. Eriksson, A.K., et al., *Psychological distress and risk of pre-diabetes and Type 2 diabetes in a prospective study of Swedish middle-aged men and women*. Diabet Med, 2008. **25**(7): p. 834-42.
17. Rhee, M.K., et al., *Unrecognized glucose intolerance is not associated with depression. Screening for Impaired Glucose Tolerance study 3 (SIGT 3)*. Diabet Med, 2008. **25**(11): p. 1361-5.
18. Kyrios, M., et al., *The influence of depression and anxiety on outcomes after an intervention for prediabetes*. Med J Aust, 2009. **190**(7 Suppl): p. S81-5.
19. Adriaanse, M.C., et al., *Diabetes-related symptom distress in association with glucose metabolism and comorbidity: the Hoorn Study*. Diabetes Care, 2008. **31**(12): p. 2268-70.
20. Xia, Q.C., et al., *[Glycometabolism of patients with depression at first episode]*. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2011. **40**(2): p. 213-6.
21. Golden, S.H., et al., *Examining a bidirectional association between depressive symptoms and diabetes*. JAMA, 2008. **299**(23): p. 2751-9.
22. Boyle, S.H., et al., *Depressive symptoms, race, and glucose concentrations: the role of cortisol as mediator*. Diabetes Care, 2007. **30**(10): p. 2484-8.